Doxorubicin pathways: pharmacodynamics and adverse effects

Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line

Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037

Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials

Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240

Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II

Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538

Doxorubicin: The good, the bad and the ugly effect

Carvalho, C., Santos, R., Cardoso, S., Correia, S., Oliveira, P., Santos, M., & Moreira, P. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803312 · Cited by 1,509 · cited 7×

Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron

Šimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70018-0 · Cited by 769

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664

Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius

Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969) · Biotechnology and Bioengineering · doi:10.1002/bit.260110607 · Cited by 622

Topoisomerase IIβ–Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane

Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612

The anthracyclines: will we ever find a better doxorubicin?

Weiss, R. B. (1992) · PubMed · Cited by 558

NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity

Wojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeböller, H., Toliat, M. R., Suk, E.-K., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.576850 · Cited by 489

P-glycoprotein—A mediator of multidrug resistance in tumour cells

Germann, U. A. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00057-3 · Cited by 405

Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.

Olson, R. D., Mushlin, P. S., Brenner, D. E., Fleischer, S., Cusack, B. J., Chang, B. K., & Boucek, R. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.10.3585 · Cited by 357

Topoisomerase levels determine chemotherapy response in vitro and in vivo

Burgess, D. J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W. R., Hannon, G. J., Lowe, S. W., & Hemann, M. T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803513105 · Cited by 300

Role of anthracyclines in the era of targeted therapy

Cortés-Funes, H., & Coronado, C. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0015-3 · Cited by 294

Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones.

Doroshow, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4514 · Cited by 269

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub4 · Cited by 265

NAD(P)H:Quinone Oxidoreductase 1 (NQO1, DT-Diaphorase), Functions and Pharmacogenetics

Ross, D., & Siegel, D. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)82008-1 · Cited by 245

Cardiac Peroxynitrite Formation and Left Ventricular Dysfunction following Doxorubicin Treatment in Mice

Weinstein, D. M., Mihm, M. J., & Bauer, J. A. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39082-2 · Cited by 229

Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis

Wallace, K. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0008-2 · Cited by 221

Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels.

Young, L. C., Campling, B. G., Cole, S. P. C., Deeley, R. G., & Gerlach, J. H. (2001) · PubMed · Cited by 220

Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly Schedule: Assessment by Endomyocardial Biopsy

TORTI, F. M., BRISTOW, M. R., HOWES, A. E., ASTON, D., STOCKDALE, F. E., CARTER, S. K., KOHLER, M., BROWN, B. W., & BILLINGHAM, M. E. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-6-745 · Cited by 215

HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy

Pritchard, K. I., Messersmith, H., Elavathil, L., Trudeau, M., O’Malley, F., & Dhesy-Thind, B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4716 · Cited by 176

The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein‐1 in cytosolic fractions from human myocardium

Minotti, G., Recalcati, S., Mordente, A., Liberi, G., Calafiore, A. M., Mancuso, C., Preziosi, P., & Cairo, G. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.7.541 · Cited by 173

Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms

Minotti, G., Recalcati, S., Menna, P., Salvatorelli, E., Corna, G., & Cairo, G. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)78025-8 · Cited by 137

Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

Lal, S., Wong, Z. W., Sandanaraj, E., Xiang, X., Ang, P., Lee, E. J. D., & Chowbay, B. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00744.x · Cited by 135

The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage

Fogli, S., Nieri, P., & Breschi, M. C. (2004) · The FASEB Journal · doi:10.1096/fj.03-0724rev · Cited by 132

Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review

Lal, S., Mahajan, A., Chen, W. N., & Chowbay, B. (2010) · Current Drug Metabolism · doi:10.2174/138920010791110890 · Cited by 131

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes

Gianni, L., Salvatorelli, E., & Minotti, G. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0013-5 · Cited by 122

Tumour cell resistance to anthracyclines ? A review

Kaye, S. B., & Merry, S. P. (1985) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00434344 · Cited by 119

Resistance to topoisomerase poisons due to loss of DNA mismatch repair

Fedier, A., Schwarz, V. A., Walt, H., Carpini, R. D., Haller, U., & Fink, D. A. (2001) · International Journal of Cancer · doi:10.1002/ijc.1356 · Cited by 117

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21

Rossi, D., Rasi, S., Franceschetti, S., Capello, D., Castelli, A., Paoli, L. D., Ramponi, A., Chiappella, A., Pogliani, E. M., Vitolo, U., et al. (2009) · Leukemia · doi:10.1038/leu.2008.398 · Cited by 116

The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin

Hasinoff, B. B., Patel, D., & Wu, X. (2003) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.08.005 · Cited by 115

New Developments in Anthracycline-Induced Cardiotoxicity

Mordente, A., Meucci, E., Silvestrini, A., Martorana, G. E., & Giardina, B. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788186228 · Cited by 112

A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance

Conrad, S., Kauffmann, H.-M., Ito, K., Leslie, E. M., Deeley, R. G., Schrenk, D., & Cole, S. P. C. (2002) · Pharmacogenetics · doi:10.1097/00008571-200206000-00008 · Cited by 110

Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood

Rajić, V., Aplenc, R., Debeljak, M., Prestor, V. V., Kuželički, N. K., Mlinarič‐Raščan, I., & Jazbec, J. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903177212 · Cited by 97

Novel SLC22A16 Polymorphisms and Influence on Doxorubicin Pharmacokinetics in Asian Breast Cancer Patients

Lal, S., Wong, Z. W., Jada, S. R., Xiang, X., Shu, X. C., Ang, P., Figg, W. D., Lee, E. J., & Chowbay, B. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.6.567 · Cited by 91

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity

Fan, L., Goh, B.-C., Wong, C., Sukri, N., Lim, S.-E., Tan, S., Guo, J.-Y., Lim, R., Yap, H., Khoo, Y.-M., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328301a869 · Cited by 89

Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution

Conrad, S., Kauffmann, H.-M., Ito, K., Deeley, R. G., Cole, S. P. C., & Schrenk, D. (2001) · Journal of Human Genetics · doi:10.1007/s100380170017 · Cited by 87

CBR1andCBR3pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients

Lal, S., Sandanaraj, E., Wong, Z. W., Ang, P., Wong, N. S., Lee, E. J. D., & Chowbay, B. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00903.x · Cited by 80

Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria.

Clementi, M. E., Giardina, B., Stasio, E. D., Mordente, A., & Misiti, F. (2003) · PubMed · Cited by 75

PXR Pharmacogenetics: Association of Haplotypes with Hepatic CYP3A4 and ABCB1 Messenger RNA Expression and Doxorubicin Clearance in Asian Breast Cancer Patients

Sandanaraj, E., Lal, S., Selvarajan, V., Ooi, L. L., Wong, Z. W., Wong, N. S., Ang, P., Lee, E. J. D., & Chowbay, B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0411 · Cited by 71

Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population

Yin, J., Huang, Q., Yang, Y., Zhang, J., Zhong, M.-Z., Zhou, H.-H., & Liu, Z. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328323f680 · Cited by 69

Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls

Robert, J. (2006) · Cell Biology and Toxicology · doi:10.1007/s10565-006-0142-9 · Cited by 62

Function-Altering SNPs in the Human Multidrug Transporter Gene ABCB1 Identified Using a Saccharomyces-Based Assay

Jeong, H., Herskowitz, I., Kroetz, D. L., & Rine, J. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030039 · Cited by 58

Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer

Singhal, S. S., Sehrawat, A., Sahu, M., Singhal, P., Vatsyayan, R., Lelsani, P. C. R., Yadav, S., & Awasthi, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24767 · Cited by 57

Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial

Choi, J., Barlow, W. E., Albain, K. S., Hong, C., Blanco, J. G., Livingston, R. B., Davis, W., Rae, J. M., Yeh, I., Hutchins, L. F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0685 · Cited by 52

Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death

Robles, A. I., Wang, X. W., & Harris, C. C. (1999) · Oncogene · doi:10.1038/sj.onc.1202862 · Cited by 52

Naturally Occurring Variants of Human CBR3 Alter Anthracycline In Vitro Metabolism

Bains, O. S., Karkling, M. J., Lubieniecka, J. M., Grigliatti, T. A., Reid, R. E., & Riggs, K. W. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160614 · Cited by 50

Role of RLIP76 in lung cancer doxorubicin resistance: I. The ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistance in lung cancer cells

Singhal, S. S., Singhal, J., Sharma, R., Singh, S. V., Zimniak, P., Awasthi, S., & Awasthi, S. (2003) · International Journal of Oncology · doi:10.3892/ijo.22.2.365 · Cited by 46

Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?

Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636

Nanomedicine review: clinical developments in liposomal applications

Beltrán-Gracia, E., López-Camacho, A., Higuera-Ciapara, I., Velázquez-Fernández, J. B., & Vallejo-Cardona, A. A. (2019) · Cancer Nanotechnology · doi:10.1186/s12645-019-0055-y · Cited by 513

Senescent Cells in Cancer Therapy: Friends or Foes?

Wang, B., Kohli, J., & Demaria, M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.004 · Cited by 508

A multi-organ chip with matured tissue niches linked by vascular flow

Ronaldson-Bouchard, K., Teles, D., Yeager, K., Tavakol, D. N., Zhao, Y., Chramiec, A., Tagore, S., Summers, M., Stylianos, S., Tamargo, M., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00882-6 · Cited by 512

Theranostic Fluorescent Probes

Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499